2024 PSMA Conference Program

Please be aware that the conference schedule is subject to change without prior notice. We recommend checking this page and our official channels for updates.

TimeDAY 1Speaker
8:00-9:00 AMBREAKFAST AND REGISTRATION 
9:00-9:05 AMIntroductionCharles J. Ryan, MD - Prostate Cancer Foundation
9:05-9:20 AMPSMA primer: the backgroundRobert Flavell, MD, PhD - University of California, San Francisco
9:20-9:35 AMDo the differences in PET agents matter?Wolfgang Fendler, MD - University of Duisburg-Essen and German Cancer Consortium (DKTK), University Hospital Essen, Germany
9:35-9:50 AMFalse positives in PSMA PETCourtney Lawhn Heath, MD - University of California, San Francisco
9:50-10:05 AMPanel discussionSpeaker panel
10:05-10:20 AMProPSMA versus PreRP – value of the prospective literatureThomas Hope, MD - University of California, San Francisco
10:20-10:35 AMEvaluation of the primary tumor with PSMA PET: time impact of the PRIMARY trialLouise Emmett, MD - St. Vincent's Hospital Sydney, Australia
10:35-10:50 AMExperience with PSMA-targeted fluorescence guided surgeryPeter Carroll, MD, MPH - University of California, San Francisco
10:50-11:05 AMIncorporating PSMA PET into RT planning: impact on definitive therapyNicholas Nickols, MD - University of California, Los Angeles
11:05-11:20 AMClinical Impact of PSMA PET prior to prostatectomyRobert Reiter, MD - University of California, Los Angeles
11:20-11:40 AMPanel discussionSpeaker panel
11:40-11:55 AMCOFFEE BREAK 
11:55 AM - 12:10 PMRole of MDT in BCR: Oligometastatic diseaseAmar Kishan, MD - University of California, Los Angeles
12:10-12:25 PMRole of PSMA PET in CRPC patientsWolfgang Fendler - University of Duisburg-Essen and German Cancer Consortium (DKTK), University Hospital Essen, Germany
12:25-12:40 PMPanel discussionSpeaker panel
12:40-12:45 PMEnhancing access to radiotheranostics for cancer care, worldwide by the Oncidium foundationAlice Viana, PhD - Oncidium Foundation
12:45-1:45 PMLUNCH BREAK 
1:45-2:00 PMPSMA PET appropriate use criteriaMichael Morris, MD - Memorial Sloan Kettering Cancer Center
2:00-2:15 PMPSMA PET standardized reportingMatthias Eiber, MD, PhD - Technische Universität München (TUM), Munich, Germany
2:15-2:30 PMTrials evaluating the impact of PSMA PET on management and outcomesAmar Kishan, MD - University of California, Los Angeles
2:30-3:45 PMTumor Board Discussion (PSMA PET) 
3:45-3:50 PMWrap up for the day

Thomas Hope, MD - University of California, San Francisco

Jeremie Calais, MD, MSc - University of California, Los Angeles

Johannes Czernin, MD - University of California, Los Angeles

3:50-4:10 PMPoster power pitches 
4:10-5:10 PMPoster session reception 
5:10-5:20 PMPoster awards 
TimeDAY 2Speaker
7:00-8:00 AMBREAKFAST AND REGISTRATION 
8:00-8:15 AMTreatment Landscape in mCRPCMatthew Rettig, MD - University of California, Los Angeles
8:15-8:30 AMPSMA radioligand therapy: the VISION and TheraP trialsMichael Morris, MD - Memorial Sloan Kettering Cancer Center
8:30-8:45 AMPSMA PET selection of patients for PSMA RLTJeremie Calais, MD, MSc - University of California, Los Angeles
8:45-9:15 AMPSMAFore, SPLASH and ECLIPSE: are they different?

Michael Morris, MD - Memorial Sloan Kettering Cancer Center

Oliver Sartor, MD - Mayo Clinic

Thomas Hope, MD - University of California, San Francisco

9:15-9:30 AMWhat is the optimal time for PSMA RLT therapyOliver Sartor, MD - Mayo Clinic
9:30-9:45 AMEnzaP and the role of AR targeted agentsLouise Emmett, MD - St. Vincent's Hospital Sydney, Australia
9:45-10:00 AMPanel discussionSpeaker panel
10:00-10:20 AMCOFFEE BREAK 
10:20-10:35 AMImaging response with PSMA RLTJeremie Calais, MD, MSc - University of California, Los Angeles
10:35-10:50 AMPost-treatment imagingLouise Emmett, MD - St. Vincent's Hospital Sydney, Australia
10:50-11:05 AMThe role of quantitative dosimetryCarlos Uribe, PhD - BC Cancer and The University of British Columbia
11:05-11:20 AMPanel discussionSpeaker panel
11:20 AM-12:35 PMTumor Board Discussion (PSMA RLT) 
12:35-1:35 PMLUNCH BREAK 
1:35-2:10 PMWorkflow considerations from the front desk to nursing including the supportive care idea

Linda Gardner, MSN, RN, VA-BC - University of California, Los Angeles

Amanda Morley, RN, BSN - University of California, San Francisco

2:10-2:25 PMPanel discussionSpeaker panel
2:25-2:40 PMTherapy resistance and combination treatmentJohannes Czernin, MD - University of California, Los Angeles
2:40-2:55 PMExperience with ImmunotherapyRahul Aggarwal, MD - University of California, San Francisco
2:55-3:10 PMNew theranostic targets in prostate cancerRobert Flavell, MD, PhD - University of California, San Francisco
3:10-3:25 PMCocktails/ portfolio of alpha and beta emitters to improve outcomesMatthias Eiber - Technische Universität München (TUM), Munich, Germany
3:25-3:40 PMRole of Ra-223 in the setting of PSMA PETOliver Sartor, MD - Mayo Clinic
3:40-4:10 PMRound Table Discussion: moderated panelSpeaker panel
4:10-4:15 PMClosing Comments

Thomas Hope, MD - University of California, San Francisco

Jeremie Calais, MD, MSc - University of California, Los Angeles

Johannes Czernin, MD - University of California, Los Angeles